Menu Close

Combating America’s diabetes crisis

n 2008, the U.S. Food and Drug Administration (FDA) released new guidance that required any drug company developing treatments for type 2 diabetes (T2D) to evaluate the cardiovascular (CV) safety of those drugs. As these trials began to read out, the data suggested that some of these medicines were not just safe but had CV benefits—with the potential to reduce the risk of CV complications, such as CV death, heart attack, stroke, and hospitalization for heart failure.